Targeting epigenetics using synthetic lethality in precision medicine

Cellular and Molecular Life Sciences : CMLS
Ee Sin Chen

Abstract

Technological breakthroughs in genomics have had a significant impact on clinical therapy for human diseases, allowing us to use patient genetic differences to guide medical care. The "synthetic lethal approach" leverages on cancer-specific genetic rewiring to deliver a therapeutic regimen that preferentially targets malignant cells while sparing normal cells. The utility of this system is evident in several recent studies, particularly in poor prognosis cancers with loss-of-function mutations that become "treatable" when two otherwise discrete and unrelated genes are targeted simultaneously. This review focuses on the chemotherapeutic targeting of epigenetic alterations in cancer cells and consolidates a network that outlines the interplay between epigenetic and genetic regulators in DNA damage repair. This network consists of numerous synergistically acting relationships that are druggable, even in recalcitrant triple-negative breast cancer. This collective knowledge points to the dawn of a new era of personalized medicine.

References

Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
Feb 28, 2003·Nature·Michal GoldbergStephen P Jackson
Feb 28, 2003·Nature·Grant S StewartStephen J Elledge
Sep 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Celina G KleerArul M Chinnaiyan
Jun 2, 2004·The Biochemical Journal·Xiaomei WangElizabeth Moran
Apr 12, 2005·European Journal of Cell Biology·Holger Hess-Stumpp
Sep 28, 2005·Nature Structural & Molecular Biology·Junran ZhangSimon N Powell
Nov 25, 2005·Current Molecular Medicine·A L Hannah
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Apr 24, 2007·Nature Structural & Molecular Biology·Estelle NicolasShiv I S Grewal
Nov 7, 2007·Nature Structural & Molecular Biology·Sean D TavernaDinshaw J Patel
Apr 10, 2009·Annual Review of Biochemistry·Cedric R Clapier, Bradley R Cairns
May 22, 2009·Journal of Cellular Biochemistry·P A Marks, W-S Xu
Sep 10, 2009·Nature Reviews. Molecular Cell Biology·Jeffrey A Simon, Robert E Kingston
Apr 13, 2010·Toxicology and Applied Pharmacology·Supratim ChoudhuriCurtis D Klaassen
Jun 25, 2010·Human Pathology·Adam D TollAgnieszka K Witkiewicz
Jul 6, 2010·Nature Genetics·Thomas ErnstNicholas C P Cross
Aug 17, 2010·Cancer Cell·Chunhua LuAnil K Sood
Sep 25, 2010·Nature·Daniel H Chitwood, Marja C P Timmermans
Oct 15, 2010·The New England Journal of Medicine·Kimberly C WiegandDavid G Huntsman
Apr 15, 2011·Nature Chemical Biology·Philip M ReaperJohn R Pollard
Oct 12, 2011·Molecular and Cellular Biology·Xiao-Yong ZhangSteven B McMahon
Jan 24, 2012·Nature Reviews. Molecular Cell Biology·Eric J Wagner, Phillip B Carpenter
Jun 5, 2012·Journal of Experimental & Clinical Cancer Research : CR·Masashi TakanoToru Sugiyama

❮ Previous
Next ❯

Methods Mentioned

BETA
ChIP-seq
xenografts

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.